INKT News and Press, MiNK Therapeutics Inc. From 04/08/24

2024-04-08 12:24:13 ET Gainers: Auddia AUUD +231% . Etao International Co Ltd. ( ETAO ) +143% . Longeveron LGVN +56% . Adlai Nortye Ltd. ( ANL ) +53% . U Power Ltd UCAR +33% . MSP Recovery LIFW +29% . Techprecision Corp TPCS +2...

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini...

A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...

2024-03-21 14:20:05 ET MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Off...

2024-03-21 07:26:40 ET More on MiNK Therapeutics Seeking Alpha’s Quant Rating on MiNK Therapeutics Historical earnings data for MiNK Therapeutics Financial information for MiNK Therapeutics Read the full article on Seeking Alpha For further det...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies Published clinical data in Nature Communications and Onco...

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer Center Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the ~70% of Gastroesophageal Cancer (GEC) Patients for Whom Current Treatments...